Immunogenicity After Second ChAdOx1 NCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle

Overview

Journal Vaccines (Basel)

Date 2021 Dec 28

PMID 34960219

Citations 5

Authors

Hyunji Choi

Sun-Min Lee

Seungjin Lim

Kyung-Hwa Shin

Taeyun Kim

Won-Joo Kim

Misook Yun

Seung-Hwan Oh

Affiliations

Soon will be listed here.

Abstract

The immune-acquired responses after vaccination vary depending on the type of vaccine and the individual. The purpose of this study was to investigate the relationship between the acquisition of immunity and the side effects, health status, and lifestyle after completion of the second dose of AZD1222. Blood samples were collected after a second dose of AZD1222. The Euroimmun Anti-SARS-CoV-2 ELISA (IgG) for anti-S1 antibody, the cPASS SARS-CoV-2 neutralizing antibody detection kit for the surrogate virus neutralization test, and the T-spot Discovery SARS-CoV-2 kit were used to identify cellular immunogenicity. Patient experience of adverse effects was investigated using questionnaires. Information on health status and lifestyle were collected from the most recent health checkup data. Generally, females experience more reactogenicity in both intensity and duration. The rash of the first shot and chills of the second shot were associated with humoral immunity. However, comprehensive adverse effects had no correlation with humoral and cellular immunity. The T-spot-positive group had a higher creatinine level, which reflects muscle mass, than the T-spot-negative group. Males presented a higher level of T-spot assays. Body mass index and age were negatively correlated with the T-spot assay and anti-S1 antibody, respectively. Immune acquisition after the second AZD1222 shot was not associated with reactogenicity. However, individuals' sex, age, and BMI were found to be associated with immunogenicity after vaccination.

Citing Articles

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity.

DSouza M, Keeshan A, Gravel C, Langlois M, Cooper C NPJ Vaccines. 2024; 9(1):226.

PMID: 39557875 PMC: 11574036. DOI: 10.1038/s41541-024-01022-8.

Association between Reactogenicity and Immunogenicity in a Vaccinated Cohort with Two mRNA SARS-CoV-2 Vaccines at a High-Complexity Reference Hospital: A Analysis on Immunology Aspects of a Prospective Cohort Study.

Saez-Penataro J, Calvo G, Bascuas J, Mosquera M, Marcos M, Egri N Vaccines (Basel). 2024; 12(6).

PMID: 38932394 PMC: 11209257. DOI: 10.3390/vaccines12060665.

Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.

Brisotto G, Montico M, Turetta M, Zanussi S, Cozzi M, Vettori R Viruses. 2023; 15(6).

PMID: 37376576 PMC: 10305214. DOI: 10.3390/v15061276.

Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study.

Choi M, Heo J, Seo Y, Yoon Y, Sohn J, Noh J Vaccines (Basel). 2023; 11(1).

PMID: 36679965 PMC: 9862064. DOI: 10.3390/vaccines11010120.

Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity.

Morgiel E, Szmyrka M, Madej M, Sebastian A, Sokolik R, Andrasiak I Vaccines (Basel). 2022; 10(5).

PMID: 35632467 PMC: 9146884. DOI: 10.3390/vaccines10050710.

References

Favaloro E . Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia. Int J Lab Hematol. 2021; 43(4):559-570. PMC: 8444734. DOI: 10.1111/ijlh.13629. View

Fisher K, Bloomstone S, Walder J, Crawford S, Fouayzi H, Mazor K . Attitudes Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. Ann Intern Med. 2020; 173(12):964-973. PMC: 7505019. DOI: 10.7326/M20-3569. View

Chia W, Zhu F, Ong S, Young B, Fong S, Bert N . Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021; 2(6):e240-e249. PMC: 7987301. DOI: 10.1016/S2666-5247(21)00025-2. View

Woods J, Vieira V, Keylock K . Exercise, inflammation, and innate immunity. Immunol Allergy Clin North Am. 2009; 29(2):381-93. DOI: 10.1016/j.iac.2009.02.011. View

Jeong S, Lee N, Lee S, Cho E, Hyun J, Park M . Comparing Results of Five SARS-CoV-2 Antibody Assays Before and After the First Dose of ChAdOx1 nCoV-19 Vaccine among Health Care Workers. J Clin Microbiol. 2021; 59(9):e0110521. PMC: 8373005. DOI: 10.1128/JCM.01105-21. View

Favaloro E, Pasalic L, Lippi G . Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT). Clin Chem Lab Med. 2021; 60(1):7-17. DOI: 10.1515/cclm-2021-1039. View

Klein S, Flanagan K . Sex differences in immune responses. Nat Rev Immunol. 2016; 16(10):626-38. DOI: 10.1038/nri.2016.90. View

Bull F, Maslin T, Armstrong T . Global physical activity questionnaire (GPAQ): nine country reliability and validity study. J Phys Act Health. 2010; 6(6):790-804. DOI: 10.1123/jpah.6.6.790. View

Montgomery R, Shaw A . Paradoxical changes in innate immunity in aging: recent progress and new directions. J Leukoc Biol. 2015; 98(6):937-43. PMC: 4661037. DOI: 10.1189/jlb.5MR0315-104R. View

10.

Jeon M, Kim J, Oh C, Lee J . Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System. J Korean Med Sci. 2021; 36(17):e114. PMC: 8093606. DOI: 10.3346/jkms.2021.36.e114. View

11.

Patel S, Molnar M, Tayek J, Ix J, Noori N, Benner D . Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2012; 4(1):19-29. PMC: 3581614. DOI: 10.1007/s13539-012-0079-1. View

12.

Ruggieri A, Anticoli S, DAmbrosio A, Giordani L, Viora M . The influence of sex and gender on immunity, infection and vaccination. Ann Ist Super Sanita. 2016; 52(2):198-204. DOI: 10.4415/ANN_16_02_11. View

13.

An K . Physical activity level in Korean adults: the Korea National Health and Nutrition Examination Survey 2017. Epidemiol Health. 2019; 41:e2019047. PMC: 6928466. DOI: 10.4178/epih.e2019047. View

14.

Gross P, Levandowski R, Russo C, Weksler M, Bonelli J, Dran S . Vaccine immune response and side effects with the use of acetaminophen with influenza vaccine. Clin Diagn Lab Immunol. 1994; 1(2):134-8. PMC: 368215. DOI: 10.1128/cdli.1.2.134-138.1994. View

15.

Young K, Gray C, Bekker L . Is obesity a risk factor for vaccine non-responsiveness?. PLoS One. 2013; 8(12):e82779. PMC: 3859613. DOI: 10.1371/journal.pone.0082779. View

16.

Sette A, Crotty S . Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021; 184(4):861-880. PMC: 7803150. DOI: 10.1016/j.cell.2021.01.007. View

17.

Zimmermann P, Curtis N . Factors That Influence the Immune Response to Vaccination. Clin Microbiol Rev. 2019; 32(2). PMC: 6431125. DOI: 10.1128/CMR.00084-18. View

18.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

19.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

20.

Bertoletti A, Bert N, Qui M, Tan A . SARS-CoV-2-specific T cells in infection and vaccination. Cell Mol Immunol. 2021; 18(10):2307-2312. PMC: 8408362. DOI: 10.1038/s41423-021-00743-3. View